Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Chemotherapy for Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
This study is currently recruiting patients.
Sponsored by: | Novacea |
---|---|
Information provided by: | Novacea |
Purpose
The purposes of this study are to determine:
Condition | Treatment or Intervention | Phase |
---|---|---|
Solid Malignancies Non-Hodgkin's Lymphoma |
Drug: AQ4N |
Phase I |
MedlinePlus related topics: Lymphoma
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety Study
Official Title: A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients with Advanced Malignancies
Expected Total Enrollment: 45
Study start: August 2004
This study is for people who have advanced cancer for which standard chemotherapy did not work or for which there are no reliably, effective treatments.
AQ4N is an experimental chemotherapy that is thought to target tumor areas with low oxygen content and low blood supply; tumor areas that are usually the most resistant to standard chemotherapy and radiation treatment. AQ4N may be beneficial in cancer treatment by interfering with a protein that is required for cells to grow and divide, causing tumors to die or to delay their growth.
All patients in this study will receive AQ4N. The dose will be increased for each new patient or group of patients until the maximum tolerated dose is reached.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |